Copyright © 2010, Research To Practice, All rights reserved. Angiogenesis Pathways to Progress? Kathy D Miller, MD Sheila D Ward Scholar of Medicine Associate.

Slides:



Advertisements
Similar presentations
Start Supplementary information S1 (animation) Proposed role of syndecan-1 in the regulation of α V β 3 integrin- and VEGF-dependent angiogenesis. This.
Advertisements

Angiogenesis.
Avances en el tratamiento del Cáncer de Pulmón Lugar de la Angiogénesis en el tratamiento de segunda linea del CPCNP Carlos Camps Inducing angiogenesis.
Notch and Cancer IPO-LISBOA CIPM Angiogenesis group Francisco Caiado Sérgio Dias.
Mesenchymal and Tissue-Specific Stem Cells ChemEng 590B: Tissue Engineering Lecture 4 January 31 st, 2013.
Therapeutic Peptides for Cardiovascular Disease and Cancer Cam Patterson, MD, MBA, FACC, FAHA Ernest and Hazel Craige Distinguished Professor of Cardiovascular.
CONVENTIONAL CANCER THERAPIES. Halsted’s Radical Mastectomy vs ‘Lumpectomy’
Figure 13.2 The Biology of Cancer (© Garland Science 2007) Hodgkins Lymphoma – A Cancer in Which 99% of the Tumor Cells Are Not Cancer Cells.
 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Lung Cancer slide presentation is not an independent educational.
Dialogue Replaces Monologue:
MBBS Cancer Biology Module 2006 Tumour Vasculature and Therapeutic Strategies Barbara Pedley.
Novel Antiangiogenic Agents: Current Clinical Development George W. Sledge, Jr. MD Indiana University Cancer Center.
Cancer stem cells IOSI Journal Club Giulia Poretti January 19, 2007.
1.Nowell, PC. The clonal evolution of tumor cell populations. Science (1976) 194: Cavenee, WK & White, RL. The genetic basis of cancer. Scientific.
Angiogenesis ↓ Metastasis. Angiogenesis--- The process of developing new blood vessels. Cancer cells (probably like all tissues) secrete substances that.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Cancer Biology.
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.
Cheil Eye Hospital Young Jeung Park, MD Jong Wook Lee, MD
Dr. Sheila Singh’s Laboratory Lab overview Operating since August 2007 Located at the Stem Cell & Cancer Research Institute at McMaster Main Campus Research.
Eun Chul Kim, M.D., Man Soo Kim, M.D. Department of Ophthalmology & Visual Science, College of Medicine, Catholic University of Korea, Seoul, Korea The.
Potential therapeutic target & predictive biomarker Oncogenic IGFBP2 Sonya Song ( 宋韦 ) Beijing Shijitan Hospital Department of Oncology The Capital Medical.
Neoplasia VI DR OSAMA I NASSIF FRCPC CONSULTANT & ASSOCIATE PROFESSOR DEPARTMENT OF PATHOLOGY, KAUH Neoplasia VI DR OSAMA I NASSIF MD,FRCPC CONSULTANT.
HOMING Ewing vs Paget Trapping vs homing (controlled arrest) “Seed and soil” Organ-specific metastatic colonization of favorable microenvironment.
Fibroblast Growth Factors (FGFs)
Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2): Krause DS, Van Etten RA N Engl J Med 2005;353(2):
Are all APL screated equal? Background image removed due to copyright considerations.
© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey A protein interaction network for ErbB receptors  ErbB.
Inflammation and cancer
TUMOR ANGIOGENESIS. Formation of new blood vessels is called angiogenesis Tumor angiogenesis is the proliferation of a network of blood vessels that penetrates.
Introduction and background
Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models Xavier CP, Pesic M, Vasconcelos MH. Curr Cancer Drug.
Angiogenic switch and progression during tumor development
A REVIEW AND UPDATE ON THE ANTI-ANGIOGENIC AGENT, ABT-510
Angiogenesis and hepatocellular carcinoma
Activating Invasion and Metastasis
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis
Types of Tumor Vascularization
Figure 3 Intracranial targeting of high-grade gliomas
Nat. Rev. Endocrinol. doi: /nrendo
HOMING
The Multifaceted Role of Perivascular Macrophages in Tumors
Ji-Liang Li, Adrian L. Harris  Cancer Cell 
Volume 26, Issue 5, Pages (November 2014)
Volume 18, Issue 4, Pages (October 2013)
Angiogenesis.
Nat. Rev. Neurol. doi: /nrneurol
Mechanisms of Vessel Pruning and Regression
Basic and Therapeutic Aspects of Angiogenesis
Angiogenesis and hepatocellular carcinoma
The role of WNT signaling in sprouting angiogenesis.
Endogenous Stimulators and Inhibitors of Angiogenesis in Gastrointestinal Cancers: Basic Science to Clinical Application  Malin Sund, Michael Zeisberg,
Giulio Francia, Urban Emmenegger, Robert S. Kerbel  Cancer Cell 
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Volume 18, Issue 4, Pages (October 2013)
Volume 21, Issue 4, Pages (April 2013)
ID Proteins Regulate Diverse Aspects of Cancer Progression and Provide Novel Therapeutic Opportunities  Radhika Nair, Wee Siang Teo, Vivek Mittal, Alexander.
TGF-β Receptor I/ ALK-5 and Pancreatic and Biliary Cancer
Ji-Liang Li, Adrian L. Harris  Cancer Cell 
Process and mechanisms of blood vessel formation.
Kristy Red-Horse, Yongping Crawford, Farbod Shojaei, Napoleone Ferrara 
Volume 22, Issue 2, Pages (August 2012)
Jair Bar, MD, PhD, Glenwood D. Goss, MD, FCPSA, FRCPC 
The VEGF Family, the Inside Story
Polarization of Tumor-Associated Macrophages: A Novel Strategy for Vascular Normalization and Antitumor Immunity  Yuhui Huang, Matija Snuderl, Rakesh.
Post-ischemic vascular repair mechanisms and the growth factors involved. Post-ischemic vascular repair mechanisms and the growth factors involved. The.
Ping-Pui Wong, Natalia Bodrug, Kairbaan M. Hodivala-Dilke 
Immunity, Inflammation, and Cancer
Normalizing the tumor microenvironment
Overview of important signalling pathways in angiogenesis and antiangiogenic agents. Overview of important signalling pathways in angiogenesis and antiangiogenic.
 Cyclooxygenase (COX) independent chemopreventive mechanisms of non-steroidal anti-inflammatory drugs (NSAIDs). *Genes with a T cell factor 4 responsive.
Presentation transcript:

Copyright © 2010, Research To Practice, All rights reserved. Angiogenesis Pathways to Progress? Kathy D Miller, MD Sheila D Ward Scholar of Medicine Associate Professor of Medicine The Indiana University Melvin and Bren Simon Cancer Center

Copyright © 2010, Research To Practice, All rights reserved. Consulting Agreement Bristol-Myers Squibb Company Speakers BureauGenentech BioOncology, Roche Laboratories Inc Disclosures for Kathy D Miller, MD

Copyright © 2010, Research To Practice, All rights reserved. Irrational exuberance Therapy “resistant to resistance” – Endothelial cells are ‘normal’ Xenograft models with widespread activity BUT – Early clinical results ‘disappointing’ – If tumors grow, there must be resistance Kerbel RS: A cancer therapy resistant to resistance. Nature 390:335-6, 1997

Copyright © 2010, Research To Practice, All rights reserved. Resistance mechanisms observed in the clinic None observed

Copyright © 2010, Research To Practice, All rights reserved. Potential mechanisms of resistance Heterogeneity in – Endothelial cells are ‘normal’ – Tumor cells – Host Tumor microenvironment Compensatory response Growth independent of angiogenesis Pharmacokinetics

Copyright © 2010, Research To Practice, All rights reserved. Endothelial heterogeneity Lessons from embryology – Brain and testes endothelia express mdr Lessons from the lab – CXC receptor expression in ‘normal’ endothelia differs based on source – Tumor-associated versus non-malignant endothelia Nearly ½ of 170 transcripts differentially expressed Expression similar but not identical between primary and metastatic sites Barrand et al FEBS Lett 374:179-83, 1995; Gille et al Blood 87:211-7, 1996; St. Croix et al Science 289: , 2000

Copyright © 2010, Research To Practice, All rights reserved. Tumor heterogeneity Genetic instability Variable sensitivity to hypoxia and hypoglycemia – Cyclic hypoxia common – Tumor cells farther from vessels may be relatively resistant to hypoxia Durand et al Cancer Res 58: , 1998 Brown et al Nat Med 7:864-8, 2001

Copyright © 2010, Research To Practice, All rights reserved. Host differences Up to 10-fold difference in response in corneal micropocket assay among different mouse strains VEGF-2578C/A and -1154G/A polymorphisms associated with increased survival with paclitaxel + bevacizumab therapy – VEGF-634G/C and -1498C/T protective from HTN Rohan et al Faseb J 14:871-6, 2000 Schneider et al, JCO 2008

Copyright © 2010, Research To Practice, All rights reserved. Tumor microenvironment Growth and angiogenesis differ in animal model based on site of implantation Local production of pro-angiogenic factors induces anti-apoptotic pathways in endothelial cells (ECs) Pericyte coverage differs Stroma as factor reservoir Impact on drug delivery Pluen et al Proc Natl Acad Sci 2001; Pozzi et al Proc Natl Acad Sci 2000; Gerber et al J Biol Chem 1998; Gohongi et al Nat Med 1999

Copyright © 2010, Research To Practice, All rights reserved. Reprinted from Cancer Cell 2005;8(4): Kerbel RS et al. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Copyright 2005, with permission from Elsevier. Compensatory response Copyright © 2010, Research To Practice, All rights reserved.

Growth independent of ‘classical’ angiogenesis Vascular mimicry Vessel cooption Intussusception Vasculogenesis Holash et al Science 1999; Patan et al Microvasc Res1996 Hendrix et al Proc Natl Acad Sci 2001; Lyden et al Nat Med 2001

Copyright © 2010, Research To Practice, All rights reserved. Model of vessel branching Copyright © 2010, Research To Practice, All rights reserved. Adapted by permission from Macmillan Publishers Ltd: Carmeliet et al. Nature Reviews 2009 ©;6:

Copyright © 2010, Research To Practice, All rights reserved. Model of vessel branching Copyright © 2010, Research To Practice, All rights reserved. Adapted by permission from Macmillan Publishers Ltd: Carmeliet et al. Nature Reviews 2009 ©;6:

Copyright © 2010, Research To Practice, All rights reserved. Model of vessel branching Copyright © 2010, Research To Practice, All rights reserved. Adapted by permission from Macmillan Publishers Ltd: Carmeliet et al. Nature Reviews 2009 ©;6:

Copyright © 2010, Research To Practice, All rights reserved. Model of vessel branching Copyright © 2010, Research To Practice, All rights reserved. Adapted by permission from Macmillan Publishers Ltd: Carmeliet et al. Nature Reviews 2009 ©;6:

Copyright © 2010, Research To Practice, All rights reserved. Differential effects of VEGF Copyright © 2010, Research To Practice, All rights reserved. Adapted by permission from Macmillan Publishers Ltd: Carmeliet et al. Nature Reviews 2009 ©;6:

Copyright © 2010, Research To Practice, All rights reserved. VEGF Inhibition Therapeutic effect based on tip and stalk cells – Inhibition of tip cell migration – Decreased stalk proliferation – Apoptosis of ECs without pericyte coverage – Impact on marrow derived progenitor release post-chemo Toxicity based on quiescent ECs?

Copyright © 2010, Research To Practice, All rights reserved. Sprouts, not sheets - role of notch Copyright © 2010, Research To Practice, All rights reserved. Adapted by permission from Macmillan Publishers Ltd: Carmeliet et al. Nature Reviews 2009 ©;6:

Copyright © 2010, Research To Practice, All rights reserved. Sprouts, not sheets - role of notch Copyright © 2010, Research To Practice, All rights reserved. Adapted by permission from Macmillan Publishers Ltd: Carmeliet et al. Nature Reviews 2009 ©;6:

Copyright © 2010, Research To Practice, All rights reserved. Conclusions Early enthusiasm has given way to clinical reality ….resistance continues Way forward continues to lie in increased knowledge of fundamental biology